Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM.CD40L.CCL21
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
GM.CD40L.CCL21 is a combination immunotherapy vaccine being investigated for advanced lung adenocarcinoma. It consists of the GM.CD40L vaccine (an allogeneic tumor cell-based vaccine generated from human bystander cell line) combined with the CCL21 chemokine. The GM.CD40L component recruits and activates dendritic cells, which then migrate to regional lymph nodes where T-cell activation occurs, leading to systemic tumor cell killing. The CCL21 chemokine helps to recruit T cells and leads to enhanced T-cell responses. This combination demonstrated additive effects in non-small cell lung cancer (NSCLC) mouse models.
- Other names
- GM.CD40L plus CCL21GM.CD40L vaccine with CCL21
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)CCR7 (C-C Motif Chemokine Receptor 7)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on GM.CD40L.CCL21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM.CD40L.CCL21.